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ed.2013.Abstract Objective: To characterize the clinical features of Vogt–Koyanagi–Harada (VKH) syn-
drome in a tertiary medical centre in western region of Kingdom of Saudi Arabia.
Method: Retrospective review of the records of patients who presented to the uveitis clinic
between December 2001 and 2011.
Results: We found 48 patients of VKH, and enrolled 32 patients who had completed at least
6 months of follow up. The mean duration of follow up was 17.34 ± 13.45 months (range 6–
60 months); 65.6% were female and 34.4% were male; and the mean age at disease onset was
33 ± 10.8 years (range 15–58 years). The majority (56.2%) had incomplete disease while 28.1%
had complete disease and 15.6% probable disease. Extra ocular symptoms were common. We cat-
egorized the patients by presentation patterns. Those in the acute stage presented with panuveitis
and bullous retinal detachment, while most of those in the convalescent stage presented with sunset
glow fundus and nummular choreo-retinal scars. Auditory manifestations were seen in patients with
chronic and recurrent stage, and cutaneous manifestations were seen in 53% of all patients.
Cataract (53%) and glaucoma (9.3%) were the main complications. Acute-stage patients were trea-
ted with systemic steroids and those with chronic and recurrent disease with immunosuppressives.
Over all, the visual prognosis was good, 62.5% of patients maintaining 20/40 or better visual acuity.
Conclusion: VKH is a common cause of uveitis in Kingdom of Saudi Arabia, often with extra-
ocular symptoms. Patients can maintain good visual acuity when treated aggressively with systemic
steroids in acute stage and immunosuppressive agents in chronic and recurrent stages.
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Vogt–Koyanagi–Harada (VKH) syndrome is a multisystem
disease of presumed autoimmune etiology. It is characterized
by chronic, bilateral, diffuse, granulomatous panuveitis with
extra ocular manifestations affecting central nervous system
(CNS) (neuro-otological symptoms like meningism, tinnitus
and decreased hearing) and integumentary system (alopecia,
poliosis and vitiligo).1–4 VKH syndrome is reported to be com-
moner in darkly pigmented races, including Asian, Middle
Eastern, Hispanic, and Native American populations.3,5–9 In
Kingdom of Saudi Arabia, VKH is common, accounting for
2.5–19.4% of all uveitis cases in various studies.10–13
VKH syndrome manifests in stages.3,14–16 Initially, patients
may present with neuro-otological symptoms, followed by
ocular and integumentary involvement. After the acute stage,
the treated patients may go into convalescent stage whereas
untreated patients may develop chronic recurrent disease with
vision-threatening complications. Integumentary manifesta-
tions appear weeks or months later. The syndrome presents
with isolated ocular involvement (probable VKH) or with ocu-
lar, CNS and integumentary involvement (complete VKH) or
ocular with either CNS or integumentary involvement (incom-
plete VKH), as determined by an International committee on
nomenclature in 2001.17
A diagnosis of VKH syndrome is suggested by pathogno-
monic clinical ﬁndings.3,14 Bilateral panuveitis along with exuda-
tive retinal detachment (RD) in the acute stage and sunset glow
fundus in chronic stage are highly speciﬁc for VKH.14 Ancillary
tests like fundus ﬂuorescein angiography (for multifocal leaks),
ultrasonography (for choroidal thickening) and lumbar puncture
(for cerebrospinal ﬂuid pleocytosis) may be helpful.3,4,14,15,18–20
The standard initial therapy for VKH is prompt, aggressive
use of systemic corticosteroids, to which the disease is espe-
cially responsive, particularly in the early stages.19–21,23 Immu-
no-modulatory agents may be needed for non-responsive
patients or when corticosteroid side-effects are not tolerated.
Visual prognosis is generally good with prompt diagnosis
and aggressive treatment.22,23
The aim of the study was to evaluate the clinical character-
istics of VKH in a tertiary medical centre in western region of
Kingdom of Saudi Arabia.Materials and Methods
A retrospective review of records of all patients with uveitis
who attended Magrabi Eye and Ear Hospitals and Centers
in Jeddah, Kingdom of Saudi Arabia, between December
2001 and 2011 was carried out to collect the patients with
the diagnosis of VKH. They were reviewed for demographic
data such as age and gender, and for clinical features such as
ocular and extra-ocular manifestations. Patients who com-
pleted a minimum of 6 months follow-up were included for
the study. All cases were classiﬁed or reclassiﬁed according
to the revised diagnostic criteria.17 All patients who presented
with acute uveitis had attended the clinic within 3 months of
onset of symptoms, whereas those with chronic and recurrent
disease had presented with symptoms of at least of 6 months
duration. All patients underwent a complete ophthalmic work
up including best corrected visual acuity, slit lamp examina-tion, applanation tonometry and dilated indirect ophthalmos-
copy, at the initial and ﬁnal visits. Fundus ﬂuorescein
angiography and ultrasonography were performed in patients
for whom the diagnosis was unclear. Indocyanine green angi-
ography was not available at our centre. Lumbar puncture
was not conducted in our patients as most refused to undergo
the procedure. Ocular complications were noted. Corticoste-
roid treatment, immunosuppressive therapy and the length of
follow-up were documented.
Results
Our retrospective review revealed 48 patients with VKH
syndrome among 587 cases of uveitis between December
2001 and December 2011 and hence, 8.1% prevalence.
Thirty two patients (64 eyes) had completed 6 months of
follow-up and were included in the analysis. The mean
duration of follow up was 17.34 ± 13.45 months (range 6–
60 months). The demographic characteristics and extra-ocu-
lar manifestations were shown in Table 1. The majority
(71.8%) were Saudi nationals and most (65.6%) of patients
were females. The mean age at disease onset was
33 ± 10.8 years (range 15–58 years). All patients had bilat-
eral ocular involvement.
The extra-ocular manifestations included neuro-otological
symptoms (meningism, tinnitus and deafness) in 19 (59%) pa-
tients and cutaneous symptoms (alopecia, poliosis and vitiligo)
in 17 (53%); nine patients had both integumentary and neuro-
otological involvements. Five (15.6%) patients had no extra
ocular manifestations.
According to the revised diagnostic criteria for VKH, 9 pa-
tients (28.1%) had complete disease, 18 (56.2%) had incom-
plete disease and 5 (15.6%) manifested probable disease.
The patients were classiﬁed into 3 groups according to the
stage at which they were seen initially.
Nine patients presented to us in acute stage (Table 2), one
with complete disease, three with probable disease and ﬁve
with incomplete disease. All patients had panuveitis and
most (77%) had exudative RD. One patient had bilateral
cystoid macular edema, three developed cataracts and two
developed macular scars. Only one patient presented with
vitiligo. None had auditory symptoms. All these patients re-
ceived topical and systemic corticosteroids and one received
pulse steroid treatment. The mean follow up was
10.3 months, when 50% of patients had better than 20/40
vision.
Ten patients presented in convalescent stage (Table 3), one
with complete disease, one with probable disease and eight
with incomplete disease. Most showed resolving inﬂammation
with nummular choreo-retinal scars and sun set glow fundus.
Two patients had macular scars and two had cataracts; vitiligo
was seen in three patients, alopecia in three and poliosis in two.
None had auditory symptoms. All patients were on tapering
doses of corticosteroids. Most had been followed up for more
than 1 year (12.6 months) when 70% of eyes had better than
20/40 vision.
Thirteen patients presented to us in chronic stage with recur-
rent inﬂammation (Table 4), seven with complete disease, one
with probable disease and ﬁve with incomplete disease. Eight
patients had anterior uveitis, ﬁve had panuveitis. Six had exu-
dative RD and two had focal exudative RD (FED). Three eyes
Table 1: Patient characteristics and extra ocular manifestations.
No. Age Nationality Sex CNS Ear Skin Stage at presentation Type
1 36 Saudi M V Convalescent Incomplete
2 58 Saudi F Acute Probable
3 15 Saudi F DH P Chr, rec Complete
4 21 Saudi F H&NP Acute Incomplete
5 33 Syrian F Convalescent Probable
6 46 Saudi F H&NP T A Chr, rec Complete
7 36 Saudi F H&NP T V Chr, rec Complete
8 46 Saudi M A Convalescent Incomplete
9 25 Ethiopian M H& NP Acute Incomplete
10 15 Saudi M H&NP A Convalescent Complete
11 19 Saudi M H& NP Acute Incomplete
12 43 Saudi M NP DH A Chr, rec Complete
13 17 Saudi M H&NP Convalescent Incomplete
14 40 Ethiopian F Acute Probable
15 21 Saudi M H Acute Incomplete
16 25 Saudi F V Chr, rec Incomplete
17 19 Sudanese F P Convalescent Incomplete
18 30 Saudi M Acute Probable
19 33 Syrian F P Convalescent Incomplete
20 34 Saudi F Chr, rec Probable
21 15 Yamani F H& NP DH A Chr, rec Complete
22 15 Saudi F H&NP Convalescent Incomplete
23 17 Saudi F A Chr, rec Incomplete
24 26 Saudi F H Chr, rec Incomplete
25 32 Palestenian F T A Chr, rec Complete
26 25 Saudi F H&NP A Chr, rec Complete
27 24 Saudi F H V Acute Complete
28 23 Yamani F V,A Convalescent Incomplete
29 36 Saudi F V Convalescent Incomplete
30 19 Saudi M H&NP T Chr, rec Incomplete
31 20 Indonesian F H&NP Chr, rec Incomplete
32 25 Saudi M H Acute Incomplete
M, male; F, female; H, headache; NP, neck pain; T, tinnitus; DH, decreased hearing; V, vitiligo; A, alopecia; P, poliosis.
26 Clinical characteristics of Vogt–Koyanagi–Harada syndromeof three patients had choroidal neovascular membrane
(CNVM) at presentation. Two of these patients with active
CNVM received intravitreal injection of Bevacizumab (Avas-
tine, Genentec), while the other patient had a scarred inactive
membrane. Three patients had bilateral disc edema and three
developed bilateral cataract. One patient had poliosis, six
had alopecia and two vitiligo; three patients presented with
decreased hearing and four with tinnitus. Imuran (Azathio-
prine) was the most commonly (11/13, 84.6%) used agent; fol-
lowed by cyclosporine in two patients and methotrexate in
one. One patient received imuran and cyclosporine. All pa-
tients were on immunosuppressive treatment in addition to
systemic steroids. Patients with anterior segment inﬂammation
were also treated with topical corticosteroids. Follow up of
these patients ranged from 6 months to 5 years with a mean
follow up was 25.3 months when 69.2% of eyes had better than
20/40 visual acuity.
At ﬁnal follow up, cataract was found in 53% of eyes, glau-
coma in 9.3%, macular scar 10.9% and CNVM in 4.6% (Ta-
ble 5). At presentation, 20/64 eyes (31%) had a best-corrected
visual acuity (BCVA) of P20/40, whereas 19/64 eyes (29.6%)
had poor BCVA (620/200). At the last visit, a BCVA ofP20/
40 was found in 40/64 eyes (62.5%) and 620/200 in only 13/64
eyes (20.3%).Discussion
In this study, VKH constituted 8.1% of all cases of uveitis pre-
senting to our clinics. We found previously that it is the second
most common cause of identiﬁable uveitic entity after Behcet’s
disease.11 Hamade et al. reported a similar prevalence (8%), 12
while other studies in Kingdom of Saudi Arabia reported a
prevalence of 2.5% and 19.4%.10,13
In our study, Saudi nationals and Arabs predominated with
two patients from Ethiopia. Although it has been reported that
VKH is common in darkly pigmented people, it is rare in sub-
Saharan Africa.5,16 Most studies suggest a female predomi-
nance among patients with VKH disease,5–14 as in our study.
Most studies report a mean age at presentation of 35–45 years
of age.1,5–9 while those in our series presented at a mean age of
33 years.
At presentation, 28.1% had complete disease, 56.2% had
incomplete disease and 15.6% probable disease, similar to
the ﬁndings of a Japanese study (11.8% were classiﬁed as com-
plete, 71% incomplete, and 8.9% as probable disease).24
Extra-ocular symptoms were common in our patients, 50%
presenting with headache and 40% with neck pain. Rao et al.14
found that 49% of their patients had headache and 36% neck
stiffness. Auditory manifestations were noted in 21% of our
Table 2: The patients presented in acute stage.
Pt No. Age Eye VA 1 Clinical ﬁndings at presentation VA 2 Follow up Complications
2 58 OD 20/30 PU 20/30 1 year Macular scar
OS CF PU, exudative RD, sub macular ﬁbrosis CF
4 21 OD 20/50 PU, CME, FED 20/100 6 months
OS 20/60 PU, CME, FED 20/100
9 25 OD CF PU 20/400 6 months Cataract
OS HM PU, exdative RD, sub macular inﬂammation HM Macular scar
11 19 OD 20/25 PU, exudative RD 20/200 1 year Cataract
OS 20/25 PU, exudative RD 20/200 Cataract
14 40 OD 20/25 PU, FED 20/25 6 months Cataract
OS 20/80 PU, exudative RD 20/80 Cataract
15 21 OD 20/100 PU, exudative RD 20/20 1 year
OS 20/60 PU 20/20
18 30 OD CF PU, exudative RD 20/400 6 months Cataract
OS CF PU, exudative RD CF Macular scar
27 24 OD 20/200 PU, exudative RD 20/30 2 years Glaucoma
OS 20/200 PU, exudative RD 20/30 Glaucoma
32 25 OD 20/200 PU, exudative RD 20/30 9 months Cataract
OS 20/100 PU, exudative RD 20/30 Cataract
VA, visual acuity; OD, right eye; OS, left eye; CF, counting ﬁngers; HM, hand motions; RD, retinal detachment; PU, panuveitis; CME, cystoid
macular edema; FED, focal exudative retinal detachment.
Patient No. 9 received I.V. methyl prednisolone.
Table 3: The patients presented in convalescent stage.
Pt No Age Eye VA 1 Clinical ﬁndings at presentation VA 2 Follow up Complication
1 36 OD 20/30 NCR, FED 20/30 1 year Glaucoma, cataract
OS 20/40 20/40 Glaucoma, cataract
5 33 OD 20/20 NCR, sunset glow fundus 20/20 1 year
OS 20/20 NCR, sunset glow fundus 20/20
8 46 OD 20/50 NCR, FED CF 1 year Macular scar
OS 20/60 NCR, FED 20/30 Cataract
10 15 OD 20/20 NCR, FED, disc edema 20/20 1 year
OS 20/20 NCR, FED, disc edema 20/20
13 17 OD 20/20 Macular scar 20/20 1 year Macular scar
OS CF CF
17 19 OD 20/50 Cataract, exudative RD CF 1 year Macular scar
OS 20/60 20/20
19 33 OD 20/20 Sunset glow fundus 20/20 6 month
OS 20/20 Sunset glow fundus 20/20
22 13 OD 20/100 Iritis 20/80 1 year Cataract
OS HM Macular scar 20/400 Macular scar
28 24 OD 20/40 NCR, sunset glow fundus 20/30 2 years Cataract
OS 20/60 NCR, sunset glow fundus 20/30 Cataract
29 36 OD 20/80 NCR, sunset glow fundus 20/80 1 year Cataract
20/30 NCR, sunset glow fundus 20/30 Cataract
VA, visual acuity; OD, right eye; OS, left eye; CF, counting ﬁngers; HM, hand motions; RD, retinal detachment; NCR scars, nummular choreo
retinal scars.
All these patients received tapering doses of systemic steroids for 6 months.
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Table 4: The patients presented with chronic recurrent inﬂammation.
Pt No. Age Eye VA 1 Clinical ﬁndings VA 2 Treatment Follow up Complication
3 15 OD 20/50 Iritis 1+ 20/50 Cyclosporine 1 year Cataract
OS 20/400 Scarred CNVM 20/400 Scarred CNVM
6 46 OD 20/50 Iritis + 4, CME, FED, NCR 20/40 Imuran 6 monyh Cataract
OS 20/50 Iritis + 4, CME, FED, NCR 20/50 Cataract
7 36 OD 20/40 Disc edema, FED 20/25 Imuran 6 month Cataract
OS 20/30 Disc edema, FED 20/30 Cataract
12 43 OD CF Iritis + 4, exudative RD 20/60 Methotrexate 1 year Cataract
OS CF Iritis + 4, exudative RD 20/30 Cataract
16 25 OD 20/50 Iritis + 4, vitriis, NCR 20/20 Imuran 2 years
OS 20/60 20/20
20 34 OD CF Iritis 1+, cataract HM Imuran 6 Glaucoma, optic atrophy
OS CF Iritis 1+, cataract CF Glaucoma, optic atrophy
21 13 OD 20/100 Irititis 1+, FED, NCR 20/25 Imuran 4 years Cataract
OS 20/200 20/25 Cataract
23 17 OD 20/40 Iritis + 4, vitriis, exudative RD 20/20 Imuran 3 years
OS 20/40 20/20
24 26 OD 20/60 Iritis 1+, DF nodules, NCR 20/20 Imuran 2 years
OS 20/100 20/20
25 32 OD 20/30 Iritis + 3, vitritis2+ 20/50 Imuran, cyclosporine 3 years Cataract
OS CF Iritis + 4, vitritis1+, disc edema, CNVM 20/30 Avastine CNVM
26 26 OD 20/100 Exudative RD 20/30 Immuran 5 years Cataract
OS 20/400 CNVM 20/400 Avastine CNVM
30 19 OD HM Exudative RD 20/40 Imuran 18 month Cataract OU
OS CF 20/30
31 20 OD 20/400 Exudative RD 20/30 Imuran 42 month Cataract OU
OS 20/400 20/30
VA, visual acuity; OD, right eye; OS, left eye; CF, counting ﬁngers; HM, hand motions; RD, retinal detachment; OU both eyes; CME, cystoid
macular edema; NCR scars, nummular choreo retinal scars; DF nodules, Dalen Fuch’s nodule; FED, focal exudative retinal detachment;
CNVM, choroidal neovascular membrane.
Table 5: Improvement of visual acuity according to the stage of disease at presentation.
Stage(No. of eyes) Pre/post treatment P20/40 20/40–20/200 620/200
Acute (18 eyes) Pre-treatment 4 (22%) 9 (50%) 5 (27%)
Post-treatment 8 (44%) 5 (27%) 5 (27%)
Convalescent (20 eyes) Pre-treatment 11 (55%) 7 (35%) 2 (1%)
Post-treatment 14 (70%) 2 (1%) 4 (205)
Chronic/recurrent (26 eyes) Pre-treatment 5 (19.2%) 9 (34.6%) 12 (46.1%)
Post-treatment 18 (69.2%) 4 (15.3%) 4 (15.3%)
Total (64 eyes) Pre-treatment 20 (31.2%) 25 (39%) 19 (29.6%)
Post-treatment 40 (62.5%) 11 (17.1%) 13 (20.3%)
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12.5% had tinnitus and 9.3% had decreased hearing while
Rao et al. found rates of 36% with tinnitus and 32% decreased
hearing. Late integumentary signs developed in 53% of our pa-
tients which is higher than the Japanese study (17.2%).24 This
may be because the majority (40%) of our patients presented
in chronic recurrent stage when the integumentary signs usu-
ally develop. In our study, 9.3% presented with poliosis,15.6% with vitiligo and 25% alopecia. Rao et al. reported
28% patients with poliosis, 20% with vitiligo and 18% alope-
cia. None of our patients had sugiura’s sign, which has been
observed mainly in Japanese patients. Rao et al. noted 5% pa-
tients (all from Japan) with sugiura’s sign in their multi-ethnic
study.14
As patients present in the acute, the convalescent or the
chronic-recurrent stage, the approach and management of
A.M. Bawazeer et al. 29each group differ. All of our patients in the acute stage pre-
sented with signs and symptoms of acute panuveitis and
77% with exudative RD. Most clinicians consider that treat-
ment for at least 6 months is required to prevent recurrences
and complications of chronic inﬂammation.3,15,20,21,23 Rao
et al. found that 50% of their patients presented with bullous
RD. In both our series and that of Rao et al., one patient pre-
sented with vitiligo in the acute stage. We found no patient
with auditory symptoms in this stage whereas; Rao et al. re-
ported that 15% of their patients had hearing loss in the acute
stage.14
Of the patients who presented in the convalescent stage, se-
ven had cutaneous symptoms (vitiligo in three, alopecia in
three and poliosis in two. None had auditory symptoms.
Of the patients who presented in chronic stage, 69% had
cutaneous symptoms, 53% had auditory symptoms. Rao
et al. reported vitiligo in 22% of their patients in chronic stage,
alopecia in 19% and poliosis in 31%, while 18% presented
with decreased hearing.14
Rao et al. reported that 75% of their patients in chronic
stage had sunset fundus and nummular choreo-retinal scars
while we found a prevalence of 80%.
Consistent with the results presented elsewhere,3,6–9,14 the
most frequent complication was cataract (53%). Other com-
plications included glaucoma (9.3%), macular scarring (10/
9%) and CNVM (4.6%). Rao et al. reported that 37% of
their patients developed cataract, 10% glaucoma and 2%
CNVM.
The incidence of neuro-otological symptoms has been re-
ported to be related to ethnicity.16 Deafness and meningism
are more prevalent in Japanese while tinnitus appears to occur
uniformly except among Hispanics who are least affected by
otological symptoms.9 In our patients all the otological symp-
toms were seen in chronic and recurrent stage and none in pa-
tients in acute and convalescent stages.
In our series, the overall visual prognosis was good with 40/
64 eyes (62.5%) maintaining a best corrected visual acuity of
20/40 or better, however, 13/64 eyes (20.3%) had poor visual
outcome.
Our study suffers from the drawbacks inherent to a retro-
spective study; however, we tried to describe the clinical fea-
tures of our small number of patients with VKH in a
rational way. A multicentre study involving the majority of
uveitis centers in Kingdom of Saudi Arabia could address
the prevalence of extra ocular symptoms in patients with
VKH syndrome.
Conclusions
Vogt–Koyanagi–Harada syndrome is a common cause of uve-
itis in Kingdom of Saudi Arabia, frequently associated with
extra-ocular manifestations. Otological symptoms appear late.
Cataract and glaucoma are the major complications. Patients
can maintain good visual acuity if they are treated aggressively
with systemic steroids in acute stage and with immunosuppres-
sive agents in chronic recurrent stages.
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